Overall Score

Scale Market Position

NTLA remains a small-cap company with a market cap of about $1.66B, limiting scale advantages versus larger biotech peers.

Revenue per share is only $0.45 TTM, indicating a still-early commercial footprint.

Pricing Power Margin Structure

Gross margin is deeply negative at -46.5% TTM, showing the business is not yet generating product-level profitability.

Operating and net margins remain severely negative at -7.1% and -6.7% TTM, respectively, suggesting no durable pricing power yet.

Capital Efficiency Returns

Return on invested capital is -52.9% TTM and return on equity is -57.8% TTM, both indicating very weak capital efficiency.

Return on assets is -46.7% TTM, reinforcing that the company is still far from earning attractive economic returns.

Balance Sheet Financial Resilience

The current ratio of 6.65x and cash ratio of 1.34x indicate strong near-term liquidity.

Debt remains modest with debt-to-equity of 0.10x and debt-to-assets of 0.09x, reducing balance-sheet risk.

Intangible Assets Switching Costs

No material intangible asset base is visible, with intangibles-to-total-assets at 0.

There is no evidence in the current data of switching costs or other customer lock-in supporting a moat.

Network Effects Ecosystem

The available metrics and news do not indicate any network effects or ecosystem advantages.

NTLA appears to compete on scientific platform execution rather than on a self-reinforcing user network.

Regulatory Ip Scientific Moat

As a gene-editing company, NTLA likely benefits from patent and regulatory barriers that can protect platform know-how.

However, the current financials do not yet show that these protections are translating into durable economic profits.